MasimoMASI
MASI
About: Masimo Corp is a technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.
Employees: 3,600
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
70% more first-time investments, than exits
New positions opened: 80 | Existing positions closed: 47
29% more call options, than puts
Call options by funds: $7.35M | Put options by funds: $5.71M
17% more repeat investments, than reductions
Existing positions increased: 134 | Existing positions reduced: 115
8% more funds holding
Funds holding: 360 [Q4 2024] → 389 (+29) [Q1 2025]
6% more capital invested
Capital invested by funds: $8.5B [Q4 2024] → $9.03B (+$535M) [Q1 2025]
4.38% more ownership
Funds ownership: 95.97% [Q4 2024] → 100.35% (+4.38%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 4 (+0) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$185
16%
upside
Avg. target
$192
21%
upside
High target
$200
26%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Raymond James Jayson Bedford | 16%upside $185 | Outperform Maintained | 7 May 2025 |
Piper Sandler Jason Bednar | 26%upside $200 | Overweight Reiterated | 7 May 2025 |
Wells Fargo Vik Chopra | 20%upside $190 | Overweight Maintained | 7 May 2025 |
Financial journalist opinion
Neutral
Business Wire
1 week ago
Masimo to Report Second Quarter 2025 Financial Results after Market Close on Tuesday, August 5
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) will release second quarter 2025 financial results for the period ended June 28, 2025, after the market closes on Tuesday, August 5, 2025. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each.
Neutral
Business Wire
3 weeks ago
Masimo Joins Innovators' Network at American Heart Association Center for Health Technology & Innovation
IRVINE, Calif.--(BUSINESS WIRE)-- #Masimo--Masimo has joined the American Heart Association's Innovators' Network, a health care technology consortium.
Neutral
GlobeNewsWire
1 month ago
MASIMO CORPORATION INVESTIGATION ALERT: Johnson Fistel, PLLP Investigates Potential Breach of Fiduciary Duties by Masimo Officers and Directors
SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Leading shareholder rights law firm Johnson Fistel, PLLP announces an investigation into potential breaches of fiduciary duties by current and former directors and officers of Masimo Corporation (NASDAQ: MASI). The investigation centers on whether Masimo's leadership failed to uphold their responsibilities to shareholders and may have violated corporate governance obligations.
Neutral
GlobeNewsWire
1 month ago
MASI INVESTIGATION ALERT: Johnson Fistel PLLP Investigates the Directors and Officers of Masimo Corporation for Breach of Fiduciary Duties
SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a shareholder rights law firm, announces it is investigating potential breaches of fiduciary duties by certain directors and officers of Masimo Corporation (NASDAQ: MASI) in relation to their obligations to the company's shareholders.
Neutral
Business Wire
1 month ago
New Study Finds Masimo SedLine® Brain Function Monitoring Offers Significant Advantages During Pediatric Anesthesia
NEUCHATEL, Switzerland--(BUSINESS WIRE)-- #Masimo--A new study found that EEG-guided anesthesia using Masimo SedLine® improved anesthesia administration in children undergoing surgery.
Neutral
Business Wire
1 month ago
MASI INVESTIGATION ALERT: Johnson Fistel PLLP Investigates the Directors and Officers of Masimo Corporation for Breach of Fiduciary Duties
SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP, a shareholder rights law firm, announces it is investigating potential breaches of fiduciary duties by certain directors and officers of Masimo Corporation (NASDAQ: MASI) in relation to their obligations to the company's shareholders. What can I do? If you are a current Masimo Corporation shareholder, you may have legal claims that may be brought on behalf of the company, against the company's directors and officers. If you wish to discuss this.
Neutral
Business Wire
2 months ago
Masimo to Present in the Jefferies Global Healthcare Conference
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management will participate in the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 1:25 p.m. Eastern time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of indus.
Neutral
GlobeNewsWire
2 months ago
MASI INVESTIGATION ALERT: Johnson Fistel PLLP Investigates the Directors and Officers of Masimo Corporation for Breach of Fiduciary Duties
SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a shareholder rights law firm, announces it is investigating potential breaches of fiduciary duties by certain directors and officers of Masimo Corporation (NASDAQ: MASI) in relation to their obligations to the company's shareholders.
Positive
Zacks Investment Research
2 months ago
Is Masimo (MASI) a Solid Growth Stock? 3 Reasons to Think "Yes"
Masimo (MASI) could produce exceptional returns because of its solid growth attributes.
Neutral
Zacks Investment Research
2 months ago
MASI Stock Slips Despite Q1 Earnings and Revenue Beat, Margins Expand
Masimo's first-quarter 2025 results continue to benefit from the strength in its Healthcare businesses despite tariff-related uncertainties.
Charts implemented using Lightweight Charts™